Core Viewpoint - The ChiNext Medical Index (970082) closed at 3882.75 points, down 0.63%, with a trading volume of 14.157 billion yuan and a turnover rate of 2.13% on February 6 [1] Group 1: Index Performance - Among the index constituents, 22 stocks rose while 28 stocks fell, with Tigermed leading the gainers at 3.06% and Aier Eye Hospital leading the decliners at 3.82% [1] - The top ten constituents of the ChiNext Medical Index include Aier Eye Hospital (9.18% weight, latest price 11.07, -3.82% change) and Tigermed (8.52% weight, latest price 65.65, +3.06% change) [1] Group 2: Market Capitalization - The total market capitalization of Aier Eye Hospital is approximately 103.232 billion yuan, while Tigermed's market capitalization is around 56.526 billion yuan [1] - Other notable companies include Mindray Medical (229.746 billion yuan) and Kanglong Chemical (55.486 billion yuan) [1] Group 3: Capital Flow - The net outflow of main funds from the ChiNext Medical Index constituents totaled 604 million yuan, while retail investors saw a net inflow of 412 million yuan [1] - The detailed capital flow shows that Tigermed had a net inflow of 14.716 million yuan from main funds, while retail investors experienced a net outflow of 1.41 million yuan [2]

10% 医药生物 沪深300 -5% 0% 5% 10% 医药生物 沪深300 标配（维持） 医药生物行业双周报（2026/1/23-2026/2/5） 第十一批国采中选结果加速落地 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 行 业 研 相关报告 证 券 研 究 报 告 医药生物行业 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% 医药生物（申万）指数走势 -35% -30% -25% -20% -15% -10% -5% 0% -35% 资料来源：iFind，东莞证券研究所 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2026 年 2 月 6 日 分析师：谢雄雄 SAC 执业证书编号： S0340 ...

【导读】深圳市上市公司数量达600家，市值超19万亿元！打造创新与高质量发展的"深圳样本" 作为资本市场服务实体经济的核心载体，深圳上市公司群体实现了规模和质量的同步跃升。 "十四五"期间，深圳境内上市公司数量增长35.03%。截至2025年10月末，总市值为12.59万亿元，占A股 上市公司总市值比例超过10%，稳居全国大中城市第二(次于北京)；总市值千亿元以上公司有20家，合 计市值为7.16万亿元。 近五年，深圳市上市公司累计贡献税费超2万亿元，近十年更是突破3.5万亿元，同时以超400万人的员 工规模筑牢区域就业"稳定器"。 2025年前三季度，深圳市上市公司累计实现营业收入5.20万亿元、净利润4577.97亿元，同比分别增长 7.36%和3.98%，营收增幅高于全国平均水平；其中制造业当家特色显著，营业收入贡献率达99.87%。 截至1月31日，深圳市市值超过千亿元的头部公司共20家。其中8家已披露2025年业绩预告信息，均为预 喜，预计2025年度盈利合计2538.97亿元。 2月3日，东鹏饮料（605499）A+H股上市；2月5日，北芯生命科创板首发上市；2月6日，卓正医疗港 股首发上市、大族 ...

Core Insights - The report highlights the contradiction faced during the "14th Five-Year Plan" period, where carbon reduction pressures are increasing while the growth rate of new energy installations is slowing down. The introduction of a national capacity price policy is expected to open up space for new energy installations and support high-yield investment options for power companies during the "14th Five-Year Plan" investment intensity [5][6][9]. Group 1: Energy Storage Industry - The national capacity price policy, issued on January 30, 2026, aims to establish a mechanism that balances power supply stability, green energy transformation, and efficient resource allocation. This policy is expected to support the development of adjustable power sources and enhance the installation of new energy [7][9]. - The report estimates that the demand for energy storage will show a high growth trend, with new energy storage installations expected to reach 66.43 GW and 189.48 GWh in 2025, representing year-on-year increases of 52% and 73% respectively [8][9]. - The capacity price policy is seen as the final piece needed for energy storage development, potentially increasing project returns from approximately 6.5% to over 8% under current subsidy conditions. This is expected to stimulate investment interest from state-owned enterprises in new energy storage projects [8][9]. Group 2: Investment Recommendations - The report suggests prioritizing investments in leading companies involved in energy storage integration and upstream battery cells, recommending firms such as Sungrow Power Supply, Trina Solar, LONGi Green Energy, JinkoSolar, CATL, and Eve Energy. It also advises monitoring companies like Haisum, Sungrow Electric, Canadian Solar, and Penghui Energy [9].

Core Insights - The 2025 Hurun China 500 list shows significant growth in company valuations, with TSMC leading as the highest valued private enterprise in China at 10.5 trillion RMB, followed by Tencent and ByteDance [1][9]. Company Performance - TSMC's value increased by 3.5 trillion RMB, driven by strong demand for artificial intelligence, advanced process technology, and a solid market position [3][11]. - Tencent's valuation rose by 1.9 trillion RMB, attributed to strong performance in gaming, advertising, and fintech [3][11]. - ByteDance's value grew by 1.8 trillion RMB, benefiting from advancements in AI [3][11]. - Alibaba's value increased by 1.2 trillion RMB, due to strategic investments in AI and cloud computing, alongside a recovery in traditional e-commerce [4][12]. - CATL's valuation rose by 690 billion RMB, supported by sustained demand in the electric vehicle market [4][12]. - Xiaomi entered the top ten with a valuation increase of 357 billion RMB, driven by growth in its automotive business and premium smartphone sales [4][12]. - Other notable companies include Cambricon, which saw a valuation increase of 370 billion RMB, and NetEase, which grew by 238 billion RMB due to strong gaming performance [4][12]. Industry Trends - The total value of the Hurun China 500 companies increased by 21 trillion RMB (38%) to reach 77 trillion RMB [2][10]. - The semiconductor industry experienced the most significant growth, surpassing the life sciences sector to become the second-largest industry in the list, while industrial products remained the largest [2][10]. - The real estate sector faced the largest decline, followed by retail [2][10]. - The average age of the top 500 companies is 29 years, indicating a relatively young corporate landscape [11]. Geographic Insights - Beijing, Shanghai, and Shenzhen are the top three cities with the most companies on the list, housing 59, 57, and 49 companies respectively [2][10]. - Suzhou emerged as the preferred manufacturing base with 68 companies, while Shanghai was the leading research and development hub with 101 companies [2][10]. New Entrants and Market Dynamics - A total of 95 companies (19%) made it to the list for the first time, with seven companies valued over 100 billion RMB [2][10]. - The threshold for entry into the 2025 Hurun China 500 increased by 7.5 billion RMB to 34 billion RMB, reflecting a 28% rise [2][10].

医药行业 2025Q4 公募基金持仓分析 [Table_Industry] 医药 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 周航(分析师) | 021-23185606 | zhouhang@gtht.com | S0880525040077 | | 张子彤(研究助理) | 021-23183273 | zhangzitong@gtht.com | S0880125042250 | 本报告导读： 2025Q4 全部基金医药股持仓占比下降，化学制剂/其他生物制品/医疗研发外包占比 居前。 投资要点： 请务必阅读正文之后的免责条款部分 [Table_Invest] 评级： 增持 [Table_Report] 相关报告 | 医药《阿斯利康宣布 2030 年前在中国投资 150 亿 | | --- | | 美元》2026.02.02 | | 医药《持续推荐创新药械产业链》2026.02.01 | | ...

Group 1 - The ChiNext 50 Index (399673.SZ) was launched on June 18, 2014, to reflect the overall performance of large-cap, liquid leading companies in the ChiNext market [3] - The index focuses on four key sectors: information technology, new energy, financial technology, and pharmaceuticals, with the top three industries being batteries (26.14%), communication equipment (23.46%), and photovoltaic equipment (7.26%), collectively accounting for 56.85% [14][24] - The index's constituent stocks are industry leaders with high representation, covering sectors such as new energy, optical modules, financial technology, PCB, and medical devices [14] Group 2 - The ChiNext 50 Index emphasizes international competitiveness and deep integration into the global industrial chain, promoting sectors with existing international competitiveness to grow stronger [18] - The index's constituent stocks have significant international operations, with overseas business income accounting for 35.17% of total revenue, higher than other major indices [25][28] - Leading companies in the index, such as CATL and Lens Technology, are key suppliers to international giants like Tesla and Apple, showcasing their strong global presence [24][26] Group 3 - The ChiNext 50 Index exhibits high elasticity and is particularly advantageous during phases of rising risk appetite, outperforming broader indices like the ChiNext Index and CSI 300 [32] - Over the past five years, the annualized return of the ChiNext 50 Index has been among the highest in its category, demonstrating its high-risk, high-reward characteristics [35] - The index is suitable for aggressive investment strategies during bull markets, aiming for higher excess returns [35] Group 4 - The valuation of the ChiNext 50 Index has returned to a reasonable range, with a current PE ratio of approximately 42, indicating a higher relative investment value [39] - The index has experienced a prolonged adjustment period, with its valuation significantly lagging behind fundamental declines, suggesting potential for future valuation and profit-driven resonance [41] - The index's constituent stocks have shown strong earnings growth, with a projected EPS compound growth rate significantly higher than other major indices [46] Group 5 - The lithium battery sector is experiencing a supply-demand resonance, driving both volume and price increases, with significant growth in demand from energy storage and new energy vehicles [55] - The communication equipment sector is benefiting from the AI data center construction, with a strong demand forecast for optical modules driven by major cloud providers [60] - The photovoltaic industry is transitioning towards high-quality development, with rising prices for raw materials like polysilicon, supported by government policies aimed at preventing "involution" in competition [67][68]

证券之星消息，2月4日医疗器械板块较上一交易日上涨0.9%，赛科希德领涨。当日上证指数报收于 4102.2，上涨0.85%。深证成指报收于14156.27，上涨0.21%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688338 | 赛科希德 | 32.11 | 10.15% | 6.36万 | | 1.97亿 | | 6638889 | 硕世生物 | 71.46 | 5.69% | 1.59万 | | 1.13亿 | | 300246 | 宝莱特 | 13.51 | 2.74% | - 16.61万 | | 2.24亿 | | 301093 | 华兰股份 | 83.15 | 2.68% | 5.14万 | | 4.17亿 | | 920009 | 丹娜生物 | 79.49 | 2.63% | 5484.98 | | 4320.40万 | | 301122 | 采纳股份 | 29.84 | 2.40% | 2.49万 | | 7407.89万 | ...

证券研究报告 从设备招投标看2026年行业投资机遇 设备拐点向上趋势明确，医疗新科技蓬勃 发展 医药生物行业 强于大市（维持） 证券分析师 叶 寅 投资咨询资格编号：S1060514100001 倪亦道 投资咨询资格编号：S1060518070001 裴晓鹏 投资咨询资格编号：S1060523090002 2026年2月4日 请务必阅读正文后免责条款 投资要点 2025年招投标高景气运行，政策与需求共振驱动增长 2025年医疗设备招投标市场在设备更新政策持续落地推动下逐步呈高景气态势，根据众成数科，全年公开招中标市场规模达1937.59亿元，yoy+24%，绝对金额仅次 于2022年高点位置。从月度趋势看，各月招采规模均处于高位，7-12月采购规模分别为134亿元/146亿元/164亿元/165亿元/207亿元/285亿元，尽管9月后受2024年 同期基数抬升影响增速有所放缓，但绝对规模仍保持高位。细分领域中，医学影像设备表现突出，2025年实现规模整体yoy+35.37%，DR、CT、超声等反弹明显；放 射治疗设备同比增长 36.34%，手术机器人、康复器械等领域也实现显著反弹。国产头部企业充分受益行业复苏 ...

2月4日，迈瑞医疗盘中上涨2.10%，截至14:10，报192.11元/股，成交11.36亿元，换手率0.50%，总市值 2329.22亿元。 资金流向方面，主力资金净流入3675.05万元，特大单买入8961.12万元，占比7.89%，卖出6070.55万 元，占比5.34%；大单买入2.99亿元，占比26.34%，卖出2.91亿元，占比25.65%。 迈瑞医疗今年以来股价涨0.87%，近5个交易日涨2.15%，近20日跌4.36%，近60日跌7.64%。 机构持仓方面，截止2025年9月30日，迈瑞医疗十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1.17亿股，相比上期减少1473.63万股。易方达创业板ETF（159915）位居第五大流通股 东，持股1169.35万股，相比上期减少195.91万股。华泰柏瑞沪深300ETF（510300）位居第六大流通股 东，持股1033.58万股，相比上期减少48.07万股。华宝中证医疗ETF（512170）位居第七大流通股东， 持股947.20万股，相比上期减少154.04万股。易方达沪深300医药ETF（512010）位居第九大流通股东， 持股75 ...